News

Aug 9, 2021

By sarahjibrin

HiFiBiO Strengthens its Senior Leadership Team in Preparation for First-in-Human Studies of Two Lead Immunoncology Programs and a Sustainable Pipeline

Jun 17, 2021

By sarahjibrin

FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease

Jun 14, 2021

By sarahjibrin

HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline with Two Lead Immuno-Oncology Programs and Validate its DIS™ Approach in the Clinic

Jun 11, 2021

By sarahjibrin

HiFiBiO Therapeutics Announces Publication in Science Advances of its High-Throughput Functional Screening for Next-Generation Cancer Immunotherapy

May 11, 2021

By sarahjibrin

HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody

Apr 12, 2021

By sarahjibrin

Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody

Apr 12, 2021

By sarahjibrin

HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers

Apr 12, 2021

By sarahjibrin

Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer

Apr 12, 2021

By sarahjibrin

Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas

Apr 7, 2021

By sarahjibrin

Luigi Manenti, MD joins HiFiBiO Therapeutics as SVP, Global Head of Clinical Development